Abstract:Background & Aim: Diallyl trisulfide (DATS) has been verified to ameliorate hepatotoxicity induced by many drugs, but the protective actions of isoniazid (INH) and rifampicin (RFP) have not been reported. We attempted to elucidate the potential effects and mechanisms of DATS against INH&RFP-caused hepatotoxicity. Methods: Male Kunming mice weighing 18-22 g were divided into 6 groups. For the hepatic-protective study, DATS (10 mg per kg, 20 mg per kg, and 40 mg per kg bw, respectively) was orally administered two hours before the INH& RFP (100 mg per kg, 100 mg per kg bw, respectively) treatments. After 11 days of treatment, 10 mice in each group were taken for the carbon clearance test, while the other 10 mice were sacrificed for the collection of serum and livers for further measurements, including the levels of serum alanine aminotransferase (ALT), aspartate transaminase (AST) and total bilirubin (T. Bili), the liver index, and liver histopathological examination. Malondialdehyde (MDA), glutathione (GSH), and the level of interleukin 1-beta (IL-1-beta) were measured, the carbon clearance test was performed and the immunohistochemistry of F4/80 marker for activated Kupffer cells (KCs) was analyzed to investigate potential mechanisms. Results: DATS co-administration significantly inhibited the increase of liver index and elevation of serum ALT, AST and T. Bili levels induced by INH& RFP, as well as improved the hepatocellular structure. The further mechanistic studies demonstrated that DATS co-administration counteracted INH& RFP-induced oxidative stress in mice, which was illustrated by the restoration of GSH levels, and the reduction of MDA levels in the liver. Furthermore, DATS co-administration reactivated the KCs inhibited by INH& RFP, which was illustrated by the increase of carbon phagocytosis, and the restoration of the number of activated KCs and IL-1-beta levels in the liver. Conclusion: DATS effectively protected the liver against INH& RFP-induced hepatotoxicity, which might be due to its antioxidant effect and enhancement of KCs' activities.

The protective effects of ursodeoxycholic acid on isoniazid plus rifampicin induced liver injury in mice.

Effects of Ursodeoxycholic Acid on Intrahepatic Cholestasis in Rats

Ursodeoxycholic Acid (UDCA) Increases Lactate Clearance and Reduces Liver Injury by Inhibiting Farnesoid X Receptor (FXR) in Hemorrhagic Shock (HS)

Protective Effects of Inonotus Obliquus Polysaccharide on Liver Injury Induced by Anti-tuberculosis Drugs in Mice

Diallyl Trisulfide Protects The Liver Against Hepatotoxicity Induced By Isoniazid And Rifampin In Mice By Reducing Oxidative Stress And Activating Kupffer Cells

Protective Effect of Pyrrolidine Dithiocarbamate on Isoniazid/rifampicin‑induced Liver Injury in Rats

Protective Effect of Ursolic Acid on the Intestinal Mucosal Barrier in a Rat Model of Liver Fibrosis

Ursodeoxycholic Acid Protects Against Arsenic Induced Hepatotoxicity by the Nrf2 Signaling Pathway

Inhibiting Hepatocyte Uric Acid Synthesis and Reabsorption Ameliorates Acetaminophen-Induced Acute Liver Injury in Mice.

The inhibition of hepatic bile acids transporters Ntcp and Bsep is involved in the pathogenesis of isoniazid/rifampicin-induced hepatotoxicity.

Ameliorative effect and mechanism of ursodeoxycholic acid on hydrogen peroxide-induced hepatocyte injury

The effect of ursodeoxycholic acid on oxidative stress level and DNase activity in rat liver after bile duct ligation

Effect of compound ursodeoxycholic acid oral liquid on cholestatic hepatitis in rats

Effects of Compound Ursodeoxycholic Acid Oral Liquid on Hepatic Fibrosis in Rats

The efficacy of Ursodeoxycholic acid therapy on moderate or severe drug-induced liver injury

Studies on Rifampicin and Isoniazid-induced Hepatotoxicity Using in Vitro Primary Hepatocytes

Protective Effects of the Bioactive Natural Product N-trans-Caffeoyldopamine on Hepatotoxicity Induced by Isoniazid and Rifampicin

Curcumin attenuates isoniazid‐induced hepatotoxicity by upregulating the SIRT1/PGC‐1α/NRF1 pathway

Effect of Compound Ursodeoxycholic Acid Oral Liquid on Alcoholic Fatty Liver Disease in Rats

A Prospective, Randomized, Controlled Clinical Trial of the Effects of Ursodeoxycholic Acid Alleviating Ischemia/reperfusion Injury in Liver Transplantation

Hepatoprotective Bile Acid Co-Drug of Isoniazid: Synthesis, Kinetics and Investigation of Antimycobacterial Potential